Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01391377|
Recruitment Status : Terminated (Tredaptive has been suspended worldwide)
First Posted : July 12, 2011
Last Update Posted : February 27, 2013
Atherosclerosis is a disorder in the body that is characterized by cholesterol plaque formation in various arteries, causing narrowing of the artery and a limitation in blood flow. Depending on which artery the plaque is in, different clinical conditions occur. In adults common areas include in the heart arteries, in the neck arteries and in the aorta and lower leg arteries. When it affects the lower limbs it is known as peripheral arterial disease - PAD.
The main symptom of PAD is called "claudication" and is described as pain or discomfort in the legs when walking. The aim of PAD treatment is to improve walking distance and quality of life in those with intermittent claudication, and to decrease long term complications including illness and death.
An important controlling factor of these cholesterol plaques is a type of cholesterol called HDL (High density lipoprotein).
This study aims to look at the effect that raising HDL for a prolonged period has on blood markers of inflammation and on the cholesterol plaque composition in patients with PAD. This investigation will also have relevance to the effects of HDL elevation on plaque composition and inflammation in other areas of the body including the heart, neck and brain arteries.
Twenty (20) PAD patients with will be recruited into the study. The investigators anticipate recruitment of all 20 patients within 12 months. The 20 PAD patients all must have significant leg pains when walking, and after review by a doctor, be determined to have narrowings in the leg artery that they will plan to operate on. Patients will be randomized to either niacin (Tredaptive, 1g/day) or matching placebo for 8 weeks (prior to operation) After the 8 week period they will then go on to receive the normal interventional treatment as planned. Blood samples will be taken at enrollment and at the 8 week mark prior to surgery. The plaque that is removed at the time of operation will also be sent to the lab for analysis.
The investigators hope to show with this study that by raising the levels of HDL with extended release niacin, there are positive effects on the amount of cholesterol in the plaque, and on the markers in the blood of inflammation and thrombosis.
The hypothesis is that elevation of HDL with Niacin will have anti-atherosclerotic actions including: Lower plaque lipid content, Reduced plaque macrophage infiltration, Reduced monocyte activation, Reduced neutrophil adhesion, Inhibition of inflammation and Inhibition of thrombotic markers.
|Condition or disease||Intervention/treatment|
|Peripheral Arterial Disease||Drug: Niacin/Laropiprant combination Drug: Sugar pill|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2014|
|Active Comparator: Niacin / Laropiprant||
Drug: Niacin/Laropiprant combination
Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
Other Name: Tredaptive
|Placebo Comparator: Sugar Pill (Placebo)||
Drug: Sugar pill
Other Name: Placebo
- Plaque composition [ Time Frame: 8 weeks after recruitment. ]After femoral arthrectomy the excised plaque will analysed for histological studies, for lipid content, immunohistochemistry, macrophage content and size and VCAM-1 staining.
- Plasma Monocyte Activation [ Time Frame: 8 weeks after recruitment ]Cd11b expression on peripheral blood monocytes will be measured as a marker of monocyte activation.
- Plasma Neutrophil Adhesion to Immobilized Fibrinogen [ Time Frame: 8 weeks after recruitment ]
- Platelet Aggregation Assays [ Time Frame: 8 weeks after recruitment ]
- Plasma Thrombotic Markers [ Time Frame: 8 weeks after recruitment ]
- Size distribution and composition of HDL [ Time Frame: 8 weeks after recruitment ]
- Ex vivo cholesterol efflux [ Time Frame: 8 weeks after recruitment ]
- Plasma lipid parameters and inflammatory markers [ Time Frame: 8 weeks after recruitment ]Lipid levels including total cholesterol, HDL, LDL and TGs, will be measured as well as ApoA1 protien and Plasma soluble ICAM-1 and soluble VCAM-1. TNF-A levels will also be measured and CRP.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01391377
|Baker IDI Heart and diabetes research institute|
|Melbourne, Victoria, Australia, 3004|
|Principal Investigator:||Bronwyn Kingwell, Bsc, PhD||Baker IDI|